iadademstat: Clinical Trials

3 trials of iadademstat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Recruiting 2, Terminated 1
Phase 11Recruiting 1

Follow iadademstat: new trials by email Literature Review of iadademstat trials Research Report on iadademstat

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)782025-08-142026-11-16
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)452025-04-082026-11-16
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma
Phase 2TerminatedFox Chase Cancer Center202022-12-212025-07-30

Conditions studied

Carcinoma, Neuroendocrine (1)  ·  Lung Neoplasms (1)  ·  Myelodysplastic-Myeloproliferative Diseases (1)  ·  Myeloproliferative Disorders (1)  ·  Polycythemia Vera (1)  ·  Primary Myelofibrosis (1)  ·  Small Cell Lung Carcinoma (1)  ·  Thrombocythemia, Essential (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Fox Chase Cancer Center (1)

Countries

United States (3)

Top investigators

Anand A Patel (1)  ·  Charles M Rudin (1)  ·  Namrata Vijavergia (1)

NIH funding

UM1CA186691 (1), UM1CA186717 (1)